Eli Lilly Forecasts 2024 Adjusted EPS Of $13.02-$13.52 Versus Prior Guidance Of $16.10-$16.60 And Consensus Of $13.47, Driven By The Acquired IPR&D Charges Incurred In Q3
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly has revised its 2024 adjusted EPS forecast to $13.02-$13.52, down from the previous guidance of $16.10-$16.60, and close to the consensus of $13.47. This adjustment is due to acquired IPR&D charges incurred in Q3.

October 30, 2024 | 10:52 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Eli Lilly has lowered its 2024 adjusted EPS forecast to $13.02-$13.52 due to acquired IPR&D charges in Q3, down from the previous guidance of $16.10-$16.60.
The downward revision in EPS guidance is significant as it reflects unexpected costs impacting profitability. This is likely to negatively affect investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100